Tango reports Phase 1/2 pancreatic cancer data, eyes Phase 3 as it posts Q2 2026 results
Tango is moving toward late-stage development of vopimetostat with daraxonrasib in pancreatic cancer after early combination data, while holding $1.0 billion in cash.
Tango Therapeutics reported second-quarter 2026 results on August 11, 2026, along with updates on its lead PRMT5 inhibitor program and pipeline plans.
The company disclosed in June that it reported initial data from vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer.1 The combination with daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival rate in this patient population, with a generally well-tolerated safety profile.1
Following those results, Tango said it is working internally and has opened discussions with regulators and Revolution Medicines to define a registrational plan for the daraxonrasib combination in MTAP-deleted pancreatic cancer.1 The company said it intends to present the full Phase 1/2 dataset at the "2026 European Society for Medical Oncology (ESMO) Congress" in Madrid, held October 23-27, 2026, according to its stated milestones.
Tango also outlined other upcoming steps, including finalizing the design of a Phase 3 randomized trial of the combination in front-line pancreatic cancer, disclosing vopimetostat lung cancer monotherapy data, releasing initial TNG456 data in glioblastoma and other cancers, and starting a Phase 1/2 combination study of vopimetostat with Erasca's ERAS-0015, all targeted for the second half of 2026.
On the corporate side, Tango named Fatma Ocak as Chief Commercialization Officer effective August 17, 2026, where she will oversee launch readiness along with medical affairs, commercial strategy, and clinical and commercial integration.1 Robert Azelby, who joined the board in June, was appointed Chairman of the Tango Board of Directors on August 6, 2026.1
Financially, Tango held $1.0 billion in cash, cash equivalents and marketable securities as of June 30, 2026, which the company said it expects will fund its current operating plan.1 Peters said the balance sheet is expected to carry the company through its planned development and commercialization preparation in pancreatic cancer, as well as ongoing work across its pipeline.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.